Cited by 185Inhalation and Respiratory Drug DeliveryTuberculosis Research and EpidemiologyAdvanced Drug Delivery Systems

The DOI matches its Crossref record; 117 of the 121 references it cites were found in a registry or an index.

Pulmonary drug delivery systems for tuberculosis treatment

Pham, Dinh-Duy, Fattal, Elias, Tsapis, Nicolas·2015·International Journal of Pharmaceutics

DOI 10.1016/j.ijpharm.2014.12.009

Open this paper in CoChat — free account

Abstract

Tuberculosis (TB) remains a major global health problem as it is the second leading cause of death from an infectious disease worldwide, after the human immunodeficiency virus (HIV). Conventional treatments fail either because of poor patient compliance to the drug regimen or due to the emergence of multidrug-resistant tuberculosis. The aim of this review is to give an update on the information available on tuberculosis, its pathogenesis and current antitubercular chemotherapies. Direct lung delivery of anti-TB drugs using pulmonary delivery systems is then reviewed since it appears as an interesting strategy to improve first and second line drugs. A particular focus is place on research performed on inhalable dry powder formulations of antitubercular drugs to target alveolar macrophages where the bacteria develop. Numerous studies show that anti-TB drugs can be incorporated into liposomes, microparticles or nanoparticles which can be delivered as dry powders to the deep lungs for instantaneous, targeted and/or controlled release. Treatments of infected animals show a significant reduction of the number of viable bacteria as well as a decrease in tissue damage. These new formulations appear as interesting alternatives to deliver directly drugs to the lungs and favor efficient TB treatment.

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2014.12.009

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
Aerosol Technology Properties, Behavior, and Measurement of Airborne Particles
Laucks, M. L. (2000) · Journal of Aerosol Science · doi:10.1016/s0021-8502(99)00571-6 · Cited by 3,426
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis
Blumberg, H. M., Burman, W. J., Chaisson, R. E., Daley, C. L., Etkind, S. C., Friedman, L. N., Fujiwara, P., Grzemska, M., Hopewell, P. C., Iseman, M. D., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,936
Diagnostic Standards and Classification of Tuberculosis in Adults and Children: This Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention was Adopted by the ATS Board of Directors, July 1999. This Statement was endorsed by the Council of the Infectious Disease Society of America, September 1999
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.16141 · Cited by 1,524
Large Porous Particles for Pulmonary Drug Delivery
Edwards, D. A., Hanes, J. S., Caponetti, G., Hrkach, J. S., Ben-Jebria, A., Eskew, M. L., Mintzes, J. D., Deaver, D. R., Lotan, N., & Langer, R. (1997) · Science · doi:10.1126/science.276.5320.1868 · Cited by 1,184
Deposition of particles in the human respiratory tract in the size range 0.005–15 μm
Heyder, J., Gebhart, J., Rudolf, G., Schiller-Scotland, C. F., & STAHLHOFEN, W. (1986) · Journal of Aerosol Science · doi:10.1016/0021-8502(86)90035-2 · Cited by 1,034
Global Tuberculosis Control 2011, WHO Report 2011
Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,022
Administration of substances to laboratory animals: routes of administration and factors to consider.
Turner, P. V., Brabb, T., Pekow, C. A., & Vasbinder, M. A. (2011) · PubMed Central · Cited by 982
Tuberculosis: Pathogenesis, Protection and Control
(1996) · Nature Medicine · doi:10.1038/nm0296-244b · Cited by 977
Development of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-W. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 904

Show all 121 references

Research works printed but not linked: 2

Kundawala, 2012, Treating tuberculosis with chitosan microparticles loaded with rifampicin as respirable powder for pulmonary delivery Indian, J. Novel Drug Deliv., 4, 57
Garcia-Contreras, 2007, Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model, Antimicrob. Agents Chemother., 51, 2830, 10.1128/AAC.01164-06 · DOI

Sorted by citations

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 566
The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases
Nisini, R., Poerio, N., Mariotti, S., Santis, F. D., & Fraziano, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00155 · Cited by 308
A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases
He, S., Gui, J., Xiong, K., Chen, M., Gao, H., & Fu, Y. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01307-x · Cited by 188
Soy Lecithin-Derived Liposomal Delivery Systems: Surface Modification and Current Applications
Le, N. T. T., Cao, V. D., Nguyen, T. N. Q., Le, T. T. H., Tran, T. T., & Thi, T. T. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194706 · Cited by 180
Versatility of hydrogel-forming microneedles in in vitro transdermal delivery of tuberculosis drugs
Anjani, Q. K., Permana, A. D., Cárcamo-Martínez, Á., Domínguez‐Robles, J., Tekko, I. A., Larrañeta, E., Vora, L. K., Ramadon, D., & Donnelly, R. F. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.12.003 · Cited by 148
A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers
Mohd, R. R., Muniandy, M. T., Zakaria, Z., Shah, K. U., Chee, C. F., Dabbagh, A., Rahman, N. A., & Wong, T. W. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116800 · Cited by 139
The formulation of nanomedicines for treating tuberculosis
Costa, A., Pinheiro, M., Magalhães, J., Ribeiro, R., Seabra, V., Reis, S., & Sarmento, B. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.012 · Cited by 123
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
Costa-Gouveia, J., Pancani, E., Jouny, S., Machelart, A., Delorme, V., Salzano, G., Iantomasi, R., Piveteau, C., Queval, C. J., Song, O., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05453-3 · Cited by 102
Pulmonary inhalation for disease treatment: Basic research and clinical translations
Wang, B., Wang, L., Yang, Q., Zhang, Y., Qinglai, T., Yang, X., Xiao, Z., Lei, L., & Li, S. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.100966 · Cited by 101
Advanced drug delivery and therapeutic strategies for tuberculosis treatment
Nair, A., Greeny, A., Nandan, A., Sah, R. K., Jose, A., Dyawanapelly, S., Junnuthula, V., Athira, K. V., & Sadanandan, P. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02156-y · Cited by 99
Critical physicochemical and biological attributes of nanoemulsions for pulmonary delivery of rifampicin by nebulization technique in tuberculosis treatment
Shah, K. U., Chan, L. W., & Wong, T. W. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1384298 · Cited by 92
Alginate modified-PLGA nanoparticles entrapping amikacin and moxifloxacin as a novel host-directed therapy for multidrug-resistant tuberculosis
Abdelghany, S. M., Parumasivam, T., Pang, A., Roediger, B., Tang, P., Jahn, K. A., Britton, W. J., & Chan, H. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.05.025 · Cited by 89
Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies
Kumar, M., Virmani, T., Kumar, G., Deshmukh, R., Sharma, A., Duarte, S. O. D., Brandão, P., & Fonte, P. (2023) · Pharmaceuticals · doi:10.3390/ph16101360 · Cited by 87
Iron-Based Metal-Organic Frameworks as a Theranostic Carrier for Local Tuberculosis Therapy
Wyszogrodzka, G., Dorożyński, P., Gil, B., Roth, W. J., Strzempek, M., Marszałek, B., Węglarz, W. P., Menaszek, E., Strzempek, W., & Kulinowski, P. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2425-2 · Cited by 82
Engineering of Nebulized Metal–Phenolic Capsules for Controlled Pulmonary Deposition
Ju, Y., Cortez‐Jugo, C., Chen, J., Wang, T., Mitchell, A. J., Tsantikos, E., Bertleff‐Zieschang, N., Lin, Y., Song, J., Cheng, Y., et al. (2020) · Advanced Science · doi:10.1002/advs.201902650 · Cited by 76
An Inhalable Theranostic System for Local Tuberculosis Treatment Containing an Isoniazid Loaded Metal Organic Framework Fe-MIL-101-NH2—From Raw MOF to Drug Delivery System
Wyszogrodzka, G., Dorożyński, P., Giovagnoli, S., Strzempek, W., Pesta, E., Węglarz, W. P., Gil, B., Menaszek, E., & Kulinowski, P. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11120687 · Cited by 75
A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug?
Maniar, K., Moideen, A., Mittal, A., Patil, A., Chakrabarti, A., & Banerjee, D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.003 · Cited by 75
Functionalized rifampicin-loaded nanostructured lipid carriers enhance macrophages uptake and antimycobacterial activity
Carneiro, S. P., Carvalho, K. V., Aguiar‐Soares, R. D. D. O., Carneiro, C. M., de Andrade, M. H. G., Duarte, R. S., & dos Santos, O. D. H. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.12.003 · Cited by 73
Pulmonary delivery of rifampicin-loaded soluplus micelles against Mycobacterium tuberculosis
Grotz, E., Tateosian, N. L., Salgueiro, J., Bernabeu, E., González, L., Manca, M. L., Amiano, N. O., Valenti, D., Manconi, M., García, V., et al. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101170 · Cited by 71
How can nanoparticles contribute to antituberculosis therapy?
Costa-Gouveia, J., Aínsa, J. A., Brodin, P. M., & Lucía, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.011 · Cited by 68
Triple co-culture of human alveolar epithelium, endothelium and macrophages for studying the interaction of nanocarriers with the air-blood barrier
Costa, A., Carvalho‐Wodarz, C. D. S., Seabra, V., Sarmento, B. F. C. C., & Lehr, C. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.04.037 · Cited by 68
Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α- d -mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy
Maretti, E., Costantino, L., Rustichelli, C., Leo, E., Croce, M. A., Buttini, F., Truzzi, E., & Iannuccelli, V. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.045 · Cited by 64
In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment?
Truzzi, E., Nascimento, T. L., Iannuccelli, V., Costantino, L., Lima, E. M., Leo, E., Siligardi, C., Gualtieri, M. L., & Maretti, E. (2020) · Nanomaterials · doi:10.3390/nano10030568 · Cited by 63
Solidified SNEDDS for the oral delivery of rifampicin: Evaluation, proof of concept, in vivo kinetics, and in silico GastroPlusTM simulation
Hussain, A., Shakeel, F., Singh, S. K., Alsarra, I. A., Faruk, A., Alanazi, F. K., & Christoper, G. V. P. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.05.061 · Cited by 63
Targeted delivery of rifampicin to tuberculosis-infected macrophages: design, in-vitro, and in-vivo performance of rifampicin-loaded poly(ester amide)s nanocarriers
Praphakar, R. A., Munusamy, M. A., Sadasivuni, K. K., & Rajan, M. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.09.080 · Cited by 62
Benzalkonium chloride alters phenotypic and genotypic antibiotic resistance profiles in a source water used for drinking water treatment
Harrison, K. R., Kappell, A. D., & McNamara, P. J. (2019) · Environmental Pollution · doi:10.1016/j.envpol.2019.113472 · Cited by 58
Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis
Chae, J., Choi, Y., Tanaka, M., & Choi, J. H. (2021) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2021.08.009 · Cited by 56
Extended Release of Highly Water Soluble Isoniazid Attained through Cocrystallization with Curcumin
Xuan, B., Wong, S. N., Zhang, Y., Weng, J., Tong, H. H. Y., Wang, C., Sun, C. C., & Chow, S. F. (2020) · Crystal Growth & Design · doi:10.1021/acs.cgd.9b01619 · Cited by 56
Lessons from black pepper: piperine and derivatives thereof
Chavarria, D., Silva, T., Silva, D., Remião, F., & Borges, F. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1118057 · Cited by 54
High dose dry powder inhalers to overcome the challenges of tuberculosis treatment
Momin, M. A. M., Tucker, I. G., & Das, S. C. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.08.061 · Cited by 53
Role of Novel Drug Delivery Vehicles in Nanobiomedicine
Tyagi, R. K. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77468 · Cited by 51
Solid Lipid Nanoparticle assemblies (SLNas) for an anti-TB inhalation treatmentA Design of Experiments approach to investigate the influence of pre-freezing conditions on the powder respirability
Maretti, E., Rustichelli, C., Romagnoli, M., Balducci, A. G., Buttini, F., Sacchetti, F., Leo, E., & Iannuccelli, V. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.07.062 · Cited by 49
Innovative Therapeutic Approaches Based on Nanotechnology for the Treatment and Management of Tuberculosis
Kia, P., Ruman, U., Pratiwi, A. R., & Hussein, M. Z. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s364634 · Cited by 51
Inhalable Antitubercular Therapy Mediated by Locust Bean Gum Microparticles
Alves, A. P. N. N., Cavaco, J., Guerreiro, F., Lourenço, J. P., da Costa, A. M. R., & Grenha, A. (2016) · Molecules · doi:10.3390/molecules21060702 · Cited by 48
Inhalable linezolid loaded PLGA nanoparticles for treatment of tuberculosis: Design, development and in vitro evaluation
Shah, S. R., Cristopher, D., Sharma, S., Soniwala, M. M., & Chavda, J. R. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102013 · Cited by 48
Analysis of cohesion forces between monodisperse microparticles with rough surfaces
Baldelli, A., & Vehring, R. (2016) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2016.06.009 · Cited by 47
Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis
Momin, M. A. M., Sinha, S., Tucker, I. G., Doyle, C., & Das, S. C. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.004 · Cited by 47
Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections
Momin, M. A. M., Tucker, I. G., Doyle, C., Denman, J. A., Sinha, S., & Das, S. C. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.02.026 · Cited by 47
Nanotechnology in Drug Discovery and Development
Gutiérrez, L., Stepien, G., Gutiérrez, L., Pérez-Hernández, M., Pardo, J., Pardo, J., Grazú, V., & de la Fuente, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12292-9 · Cited by 51
DPI formulations for high dose applications – Challenges and opportunities
Scherließ, R., & Etschmann, C. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.06.038 · Cited by 46
Antimicrobial polymeric biomaterials based on synthetic, nanotechnology, and biotechnological approaches
Rojo, L., García‐Fernández, L., Aguilar, M. R., & Vázquez‐Lasa, B. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102752 · Cited by 45
Development of Inhalable Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in Microparticulate System for Antituberculosis Drug Delivery
Miranda, M. S., Rodrigues, M. T., Domingues, R. M. A., Costa, R. R., Paz, E., Rodríguez‐Abreu, C., Freitas, P. P., Almeida, B. G., Carvalho, M. A., Gonçalves, C. M., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800124 · Cited by 45
Chronic respiratory diseases: An introduction and need for novel drug delivery approaches
Shukla, S. D., Vanka, K. S., Chavelier, A., Shastri, M. D., Tambuwala, M. M., Bakshi, H. A., Pabreja, K., Mahmood, M. Q., & O’Toole, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820658-4.00001-7 · Cited by 53
Inhalable liposomes ofGlycyrrhiza glabraextract for use in tuberculosis: formulation,in vitrocharacterization,in vivolung deposition, andin vivopharmacodynamic studies
Viswanathan, V., Pharande, R. R., Bannalikar, A. S., Gupta, P., Gupta, U. D., & Mukne, A. (2018) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2018.1513025 · Cited by 43
Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19
Alipour, S., Mahmoudi, L., & Ahmadi, F. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01251-1 · Cited by 43
The Anti-Tuberculosis Agents Under Development and the Challenges Ahead
Kumar, D., Negi, B., & Rawat, D. S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.128 · Cited by 42
Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery
Miranda, M. S., Rodrigues, M. T., Domingues, R. M. A., Torrado, E., Reis, R. L., Pedrosa, J., & Gomes, M. E. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.09.004 · Cited by 43
Spray-drying of konjac glucomannan to produce microparticles for an application as antitubercular drug carriers
Guerreiro, F., Pontes, J. F., da Costa, A. M. R., & Grenha, A. (2018) · Powder Technology · doi:10.1016/j.powtec.2018.09.068 · Cited by 42
Beyond “Big Eaters”: The Versatile Role of Alveolar Macrophages in Health and Disease
Hetzel, M., Ackermann, M., & Lachmann, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073308 · Cited by 37
Pulmonary delivery of pyrazinamide-loaded large porous particles
Pham, D.-D., Grégoire, N., Couet, W. R., Gueutin, C., Fattal, E., & Tsapis, N. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.021 · Cited by 39
Self-citation
Polymeric nanotherapeutics acting at special regions of body
Feczkó, T. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102597 · Cited by 39
Enhanced antitubercular activity, alveolar deposition and macrophages uptake of mannosylated stable nanoliposomes
Hamed, A. I., Osman, R., Al‐Jamal, K. T., Holayel, S. M., & Geneidi, A. S. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.03.032 · Cited by 37
Metal–Organic Framework Microsphere Formulation for Pulmonary Administration
Fernández-Paz, C., Rojas, S., Salcedo‐Abraira, P., Simón‐Yarza, T., Remuñán‐López, C., & Horcajada, P. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c07356 · Cited by 37
Fullerene nanoparticles: a promising candidate for the alleviation of silicosis-associated pulmonary inflammation
Liu, S., Chen, D., Li, X., Guan, M., Zhou, Y., Li, L., Jia, W., Zhou, C., Shu, C., Wang, C., et al. (2020) · Nanoscale · doi:10.1039/d0nr04401f · Cited by 37
Nanopolymersomes as potential carriers for rifampicin pulmonary delivery
Moretton, M. A., Cagel, M., Bernabeu, E., González, L., & Chiappetta, D. A. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.10.049 · Cited by 36
Rifampicin Nanoformulation Enhances Treatment of Tuberculosis in Zebrafish
Trousil, J., Syrová, Z., Dal, N. K., Rak, D., Konefał, R., Pavlová, E., Matějková, J., Cmarko, D., Kubíčková, P., Pavliš, O., et al. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b00214 · Cited by 36
Mannose-Decorated Solid-Lipid Nanoparticles for Alveolar Macrophage Targeted Delivery of Rifampicin
Bera, H., Zhao, C., Tian, X., Cun, D., & Yang, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030429 · Cited by 35
Targeted delivery of anti-tuberculosis drugs to macrophages: targeting mannose receptors
Filatova, L. Y., Klyachko, N. L., & Kudryashova, E. V. (2018) · Russian Chemical Reviews · doi:10.1070/rcr4740 · Cited by 35
Nano-based drug delivery optimization for tuberculosis treatment: A review
Dahanayake, M. H., & Jayasundera, A. C. A. (2020) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2020.106127 · Cited by 35
A comparative physicochemical, morphological and magnetic study of silane-functionalized superparamagnetic iron oxide nanoparticles prepared by alkaline coprecipitation
Mireles, L. K., Sacher, E., Yahia, L., Laurent, S., & Stanicki, D. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.12.002 · Cited by 35
Current advances in drug delivery of nanoparticles for respiratory disease treatment
de Menezes, B. R. C., Rodrigues, K. F., Schatkoski, V. M., Pereira, R. M., Ribas, R. G., Montanheiro, T. L. D. A., & Thim, G. P. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01783c · Cited by 34
Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study
Zhou, S.-F., Niu, N., Yin, J., Yang, Y., Wang, Z., Zhou, Z.-W., He, Z., Chen, X., Zhang, X., Duan, W., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s79369 · Cited by 34
Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates
Carvalho, R. D. S. F., Pereira, M. A., Linhares, L. D. A., Nogueira, M. C. D. B. L., Cavalcanti, I. M. F., Santos-Magalhães, N. S., & Montenegro, L. M. L. (2016) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760150454 · Cited by 33
A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation
Khadka, P., Dummer, J. F., Hill, P. C., Katare, R., & Das, S. C. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01238-y · Cited by 32
Drug Delivery for tuberculosis: is Inhaled Therapy the Key to success?
Traini, D., & Young, P. M. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0050 · Cited by 31
Active pulmonary targeting against tuberculosis (TB) via triple-encapsulation of Q203, bedaquiline and superparamagnetic iron oxides (SPIOs) in nanoparticle aggregates
Poh, W., Rahman, N. B. A., Ostrovski, Y., Sznitman, J., Pethe, K., & Loo, S. C. J. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1676841 · Cited by 29
Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: Therapeutic assessment in a murine model of tuberculosis infection
Grenha, A., Alves, A. D., Guerreiro, F., Pinho, J. O., Simões, S., Almeida, A. J., & Gaspar, M. M. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.11.009 · Cited by 29
Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis
Verma, N., Arora, V., Awasthi, R., Chan, Y., Jha, N. K., Thapa, K., Jawaid, T., Kamal, M., Gupta, G., Liu, G., et al. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103690 · Cited by 33
Spray-Dried Nanolipid Powders for Pulmonary Drug Delivery: A Comprehensive Mini Review
Elella, M. H. A., Khatib, A. O. A., & Al-Obaidi, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050680 · Cited by 29
Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment
Kalombo, L., Lemmer, Y., Semete‐Makokotlela, B., Ramalapa, B., Nkuna, P., Booysen, L., Naidoo, S., Hayeshi, R. K., Verschoor, J. A., & Swai, H. (2019) · Nanomaterials · doi:10.3390/nano9081167 · Cited by 28
Strategies for lipid-based nanocomposites with potential activity against Mycobacterium tuberculosis: Microbial resistance challenge and drug delivery trends
Hatae, A. C., Roque‐Borda, C. A., & Pavan, F. R. (2023) · OpenNano · doi:10.1016/j.onano.2023.100171 · Cited by 28
Future of nanomedicines for treating respiratory diseases
Scherließ, R. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1553955 · Cited by 27
Liposomes-and niosomes-based drug delivery systems for tuberculosis treatment
Bekraki, A. I. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819811-7.00007-2 · Cited by 28
Dry powder inhalation formulation of chitosan nanoparticles for co-administration of isoniazid and pyrazinamide
Changsan, N., & Sinsuebpol, C. (2020) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2020.1852570 · Cited by 27
Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation
Garg, T., Goyal, A. K., Rath, G., & Murthy, R. S. R. (2015) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2015.1081613 · Cited by 26
Electrostatically entrapped colistin liposomes for the treatment of Pseudomonas aeruginosa infection
Yang, L., Tang, C., Zhang, E., & Yang, L. (2016) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2016.1228666 · Cited by 25
Pharmacokinetics and in vivo distribution of optimized PLGA nanoparticles for pulmonary delivery of levofloxacin
Shah, S. R., Prajapati, H. R., Sheth, D. B., Gondaliya, E. M., Vyas, A. J., Soniwala, M. M., & Chavda, J. R. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13275 · Cited by 25
Breathing new life nanomedicines for pulmonary drug delivery: targeting approaches, experimental models, and regulatory aspects
Gholap, A. D., Pardeshi, S. R., Giram, P. S., Nangare, S., Sodha, S., Kapare, H. S., More, M. P., Sonar, Y. A., Shukla, R., Naik, J., et al. (2025) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-025-00646-6 · Cited by 25
Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis
Man, D. K.-W., Chow, M. Y. T., Casettari, L., Juarrero, M. G., & Lam, J. K. W. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.013 · Cited by 26
Efficient loading of ethionamide in cyclodextrin-based carriers offers enhanced solubility and inhibition of drug crystallization
Wankar, J., Salzano, G., Pancani, E., Benkovics, G., Malanga, M., Manoli, F., Gref, R., Fenyvesi, É., & Manet, I. G. J. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.041 · Cited by 24
Drug delivery systems for fluoroquinolones: New prospects in tuberculosis treatment
Le‐Deygen, I. M., Скуредина, А. А., & Kudryashova, E. V. (2017) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162017050077 · Cited by 24
Evaluating the biomolecular interaction between delamanid/formulations and human serum albumin by fluorescence, CD spectroscopy and SPR: Effects on protein conformation, kinetic and thermodynamic parameters
Tongkanarak, K., Loupiac, C., Neiers, F., Chambin, O., & Srichana, T. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.113964 · Cited by 23
In silico identification and synthesis of a multi-drug loaded MOF for treating tuberculosis
Acharya, A. P., Sezginel, K. B., Gideon, H. P., Greene, A. C., Lawson, H., Inamdar, S., Tang, Y., Fraser, A. J., Patel, K. V., Liu, C., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.024 · Cited by 22
Chitosan-based pulmonary particulate systems for anticancer and antiviral drug carriers: A promising delivery for COVID-19 vaccines
Tousian, B., & Khosravi, A. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101146 · Cited by 21
Nano-Drug Delivery Systems: Possible End to the Rising Threats of Tuberculosis
Sheikh, B. A., Bhat, B. A., Alshehri, B., Mir, R. A., Mir, W. R., Parry, Z. A., & Mir, M. A. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3201 · Cited by 20
Polymeric micelle-based drug delivery systems for tuberculosis treatment
Gorain, B., Choudhury, H., Sisinthy, S. P., & Kesharwani, P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819811-7.00011-4 · Cited by 20
Influence of Drug Properties and Routes of Drug Administration on the Design of Controlled Release System
Indurkhya, A., Patel, M., Sharma, P. A., Abed, S. N., Shnoudeh, A. J., Maheshwari, R., Deb, P. K., & Tekade, R. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814423-7.00006-x · Cited by 20
Lipid nanoparticles with improved biopharmaceutical attributes for tuberculosis treatment
Gordillo-Galeano, A., Ospina-Giraldo, L. F., & Mora‐Huertas, C. E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120321 · Cited by 19
The Activity of a Hexameric M17 Metallo-Aminopeptidase Is Associated With Survival of Mycobacterium tuberculosis
Corrêa, A. F., Bastos, I. M. D., Neves, D., Kipnis, A., Junqueira‐Kipnis, A. P., & Santana, J. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00504 · Cited by 18
The long and winding road to inhaled TB therapy: not only the bug’s fault
Giovagnoli, S., Schoubben, A., & Ricci, M. (2016) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2016.1272119 · Cited by 17
The Role of Metallic Nanoparticles in Inhibition of Mycobacterium Tuberculosis and Enhances Phagosome Maturation into the Infected Macrophage
Jafari, A., Nagheli, A., Foumani, A. A., Tehrani, B. S., & Goswami, R. (2020) · Oman Medical Journal · doi:10.5001/omj.2020.78 · Cited by 17
Solubility Enhancement and Inhalation Delivery of Cyclodextrin-Based Inclusion Complex of Delamanid for Pulmonary Tuberculosis Treatment
Patil, S. M., Barji, D. S., Chavan, T., Patel, K., Collazo, A. J., Prithipaul, V., Muth, A., & Kunda, N. K. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02510-1 · Cited by 17
Manufacturing processes for polymeric micro and nanoparticles and their biomedical applications
Braz, A. L., & Ahmed, I. (2017) · AIMS bioengineering · doi:10.3934/bioeng.2017.1.46 · Cited by 17
Preference of inhalants over pills/injections among pulmonary tuberculosis patients in Western India: A cross-sectional study
Ahuja, N. A., Sznajder, K. K., Patil, R., & Shaikh, B. (2021) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2021.100234 · Cited by 16
Carrier Effect in Development of Rifampin Loaded Proliposome for Pulmonary Delivery: A Quality by Design Study
Parhizkar, E., Sadeghinia, D., Hamishehkar, H., Yaqoubi, S., Nokhodchi, A., & Alipour, S. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.032 · Cited by 16
Development and validation of a RP-HPLC method for simultaneous quantification of bedaquiline (TMC207), moxifloxacin and pyrazinamide in a pharmaceutical powder formulation for inhalation
Momin, M. A. M., Rangnekar, B., & Das, S. C. (2018) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2018.1437748 · Cited by 16
Pulmonary Delivery of Linezolid Nanoparticles for Treatment of Tuberculosis: Design, Development, and Optimization
Shah, S. R., Maheshwari, H., Soniwala, M. M., & Chavda, J. R. (2020) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-020-09491-9 · Cited by 16
Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics
Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 16
Data-Driven Prediction of the Formation of Co-Amorphous Systems
Fink, E., Brunsteiner, M., Mitsche, S., Schröttner, H., Paudel, A., & Zellnitz, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020347 · Cited by 15

Authors: Pham, D.-D., Fattal, E., & Tsapis, N.
Affiliations: Centre National de la Recherche Scientifique (FR)
Corresponding author: Pham, Dinh-Duy
Tsapis, Nicolas
ORCID: Fattal, Elias
Tsapis, Nicolas
Venue: International Journal of Pharmaceutics
Publisher: Elsevier BV
Published: 2015-01
Volume: 478
Issue: 2
Pages: 517-529
ISSN: 0378-5173 (ISSN-L)
DOI: 10.1016/j.ijpharm.2014.12.009
OpenAlex: W2076894650
Cited by: 185
References: 121
Citations by year: 2026: 5 · 2025: 11 · 2024: 11 · 2023: 23 · 2022: 15 · 2021: 12 · 2020: 26 · 2019: 25 · 2018: 16 · 2017: 14 · 2016: 18 · 2015: 9
FWCI: 2.34
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: International Journal of Pharmaceutics (publishedVersion)
PubMed (publishedVersion)
Funders: ANR (ANR-10-LABX-33)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords: pulmonary drug delivery, tuberculosis, antitubercular agents, dry powder inhaler, liposomes, microparticles, nanoparticles, alveolar macrophages, multidrug-resistant tuberculosis, medication adherence, controlled drug release, targeted drug delivery
MeSH terms: Administration, Inhalation, Animals, Antitubercular Agents, Humans, Powders, Tuberculosis, Pulmonary, Drug Delivery Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pulmonary drug delivery systems for tuberculosis treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks